Beijing Leadman Biochemistry Co Ltd
SZSE:300289
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
CN |
B
|
Beijing Leadman Biochemistry Co Ltd
SZSE:300289
|
2.5B CNY | 14.6 | |
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 14.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 26.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 27.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 21 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 37.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.8B USD | 11.4 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | -16.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -77.6 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 23 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 25.7 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.